Cap Biotechnology: Disclosure of cumulative litigation and arbitration cases, involving a total amount of 4.16 billion yuan.

Cap Biotechnology announced that as of the disclosure date of the announcement, the company and its subsidiaries have been involved in a total of 102 litigation and arbitration cases over the past twelve months, involving a total amount of 416 million yuan, accounting for 10.12% of the company's shareholders' equity attributed in the most recent audited period. Among them, there are 69 cases where the company and its subsidiaries are the plaintiffs, involving an amount of 357 million yuan; there are 33 cases where the company and its subsidiaries are the defendants, involving an amount of 59 million yuan. Currently, there are no significant litigation or arbitration cases with individual amounts exceeding 10% of the last audited net assets and exceeding 10 million yuan. Some cases have not been heard or settled, and there is uncertainty regarding their impact on the company's profits.